• If you are citizen of an European Union member nation, you may not use this service unless you are at least 16 years old.

  • You already know Dokkio is an AI-powered assistant to organize & manage your digital files & messages. Very soon, Dokkio will support Outlook as well as One Drive. Check it out today!



Page history last edited by PBworks 17 years, 9 months ago



BSR Guideline 2004



Initiation: 400 mg daily until response

Maintenance: 200 mg daily

Maximum dosage: 6.5 mg/kg/day

It is more palatable after food. Orange juice may mask the bitter after taste.




Base line assessment only - U&E and LFT

Enquiries about visual impairment and recording of near visual acuity will be done in the Rheumatology Clinic with yearly evaluations thereafter. If visual impairment is present at baseline, assessment by an optomotrist is advised.


Referral to Ophthalmologistist is appropriate if:

1. Visual impairment/eye disease detected at baseline confirmed by optomotrist

2. Change in acuity or blurred vision whilst on treatment

(Stop treatment until assessed)

3. Children



Pregnancy, pre-existing maculopathy. It must not be co-prescribed with Amiodarone (risk of ventricular arrhythmia’s)




Liver and kidney disease, and in sever GI, neurological and blood disorders.




Amiodarone (see contraindications)

Antacids reduce its absorption

Antagonism of anticonvulsant effect

Increase plasma concentration of Digoxin

Increased risk of Cyclosporin toxicity if co-prescribed



Side Effects

Common effects are in bold type

Mucocutaneous - pruritis erythematous rash seen after treatment commenced.

Blue-black pigmentation of skin

Haematological - thrombocytopenia, agranulocytosis (very rare)

Gastrointestinal - NAUSEA, DIARRHOEA, abdominal cramps

Ocular - Cycloplegia, keratopathy (reversible), irreversible retinopathy

/maculopathy, photophobia – advise sunglasses in bright


Other - headache, bleaching of skin/hair, proximal myopathy,

peripheral neuropathy

Comments (0)

You don't have permission to comment on this page.